High-Purity Canola Protein: Burcon’s New Achievement
Category: Stocks Total Views: 82By : Dominic Sanders Updated: 07-29-2024
Burcon NutraScience Achieves Milestone in Canola Protein Production
Leader in plant-based protein technologies, Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) has effectively finished its first end-to-end validation trial for manufacturing high-purity canola protein isolate. For Burcon's goal of releasing creative, plant-based protein solutions onto the market, this success represents a major forward step.
Commercialization of Canola Protein Technology... Read More
Cosa's Orbit Project Gains Untapped Exploration Areas
Category: Stocks Total Views: 84By : Caleb Price Updated: 07-29-2024
Acquisition of Mineral Claims in Athabasca Basin
Skyharbour Resources LTD. has signed an asset purchase agreement with Cosa Resources Corp. Signed July 26, 2024, the agreement calls for acquiring two mineral claims in the Athabasca Basin, Saskatchewan. With 12,718 hectares, these claims will double the footprint of the Orbit uranium project. With this purchase, Cosa will be able to increase its eight kilometer control of untested strike length. The claims follow trend with uranium... Read More
Hyperfast Title Joins reAlpha's AI Homebuying Platform
Category: Stocks Total Views: 131By : Riley Hayes Updated: 07-29-2024
reAlpha Acquires 85% Stake in Hyperfast Title, LLC
85% of Hyperfast Title, LLC. has been acquired by reAlpha Tech Corp. Hyperfast calls Florida, Virginia, and Tennessee home. This purchase expands the portfolio of reAlpha with title and settlement services. Re Alpha is renowned for creating real estate artificial intelligence technologies. The purchase from Madison Settlement Services fits the expansion plan of reAlpha. This action enhances the homebuying market offerings from reA... Read More
New Alzheimer's Treatment: Anavex's Blarcamesine Success
Category: Stocks Total Views: 99By : Addison Perry Updated: 07-29-2024
Anavex Life Sciences Reports Promising Results for Alzheimer's Treatment
From its Phase IIb/III study on blarcamesine (ANAVEX®2-73), a medication for early Alzheimer's disease (AD), Anavex Life Sciences Corp. (Nasdaq: AVXL) has reported encouraging findings. Leading neurology specialist Dr. Marwan Noel Sabbagh delivered the data at the 2024 Alzheimer's Association International Conference (AAIC). Taken once daily, blarcamesine has shown great promise in halting the... Read More
Windtree's Latest Advances: Istaroxime Clinical Trials
Category: Stocks Total Views: 213By : Lucas Young Updated: 07-28-2024
Windtree Therapeutics Updates Istaroxime Clinical Development and Trial Data
Providing a thorough update on the clinical and business development of istaroxime, Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company committed to developing creative therapies for critical diseases, has This first-in-class treatment seeks to raise blood pressure, preserve or increase renal function, and strengthen systolic contraction and diastolic relaxation of the heart. In three Ph... Read More